Management of Non-ST-Elevation Myocardial Infarction (NSTEMI)

Initial Management

• The American College of Cardiology recommends administering aspirin 162-325 mg immediately upon presentation, as well as anticoagulation with unfractionated heparin, and risk stratification to determine whether an early invasive or conservative strategy is appropriate, followed by dual antiplatelet therapy and secondary prevention measures 1, 2, 3
• The American Heart Association suggests admitting patients to a monitored unit with continuous rhythm monitoring for at least 24 hours 4
• Supplemental oxygen should be administered if arterial oxygen saturation is <90% 4
• Nitroglycerin should be considered for ongoing ischemic symptoms unless contraindicated 4
• Beta-blockers should be initiated to reduce myocardial oxygen demand by decreasing heart rate, blood pressure, and myocardial contractility 4

Antiplatelet Therapy

• The American College of Cardiology recommends continuing aspirin indefinitely (Level of Evidence: A) 1, 2, 3
• A loading dose of clopidogrel (300 mg) should be administered if an early conservative strategy is selected or if PCI is planned and not started before diagnostic angiography (Level of Evidence: A) 2, 3

Anticoagulant Therapy

• The American College of Cardiology recommends administering unfractionated heparin (UFH), enoxaparin, fondaparinux, or bivalirudin 1, 2, 3
• For patients managed medically, intravenous UFH should be continued for at least 48 hours or until discharge if given before diagnostic angiography (Level of Evidence: A) 2, 3
• Enoxaparin should be continued for the duration of hospitalization, up to 8 days, if given before diagnostic angiography (Level of Evidence: A) 2, 3
• Fondaparinux should be continued for the duration of hospitalization, up to 8 days, if given before diagnostic angiography (Level of Evidence: B) 2, 3

Management Strategy Selection

• An early invasive strategy (angiography within 24-48 hours) is indicated for patients with refractory angina, hemodynamic or electrical instability, elevated cardiac biomarkers, or high GRACE or TIMI risk score 2, 3, 4
• A conservative strategy is appropriate for lower-risk patients without ongoing ischemia or patients with significant comorbidities where risks of invasive approach outweigh benefits 4

Post-Angiography Management

• If PCI is selected, aspirin should be continued (Level of Evidence: A) and a loading dose of P2Y12 inhibitor should be administered if not started before diagnostic angiography (Level of Evidence: A) 1, 2, 3
• If CABG is selected, aspirin should be continued (Level of Evidence: A) and clopidogrel should be discontinued 5-7 days before elective CABG (Level of Evidence: B) 1, 2, 5
• If medical therapy is selected, aspirin should be continued (Level of Evidence: A) and a loading dose of clopidogrel should be administered if not given before diagnostic angiography (Level of Evidence: A/B) 1, 2, 3

Long-term Management

• Left ventricular ejection fraction (LVEF) should be measured (Level of Evidence: B) 2, 3
• If LVEF ≤0.40, diagnostic angiography should be considered (Level of Evidence: B) 3
• If LVEF >0.40, a stress test should be considered (Level of Evidence: B) 3
• ACE inhibitors should be initiated for patients with heart failure, LV dysfunction (LVEF <0.40), hypertension, or diabetes 4
• ARBs should be considered for ACE inhibitor-intolerant patients 4

NSTEMI Management Guidelines

Initial Management

• The American College of Cardiology recommends considering morphine sulfate intravenously for uncontrolled ischemic chest discomfort despite nitroglycerin in patients with NSTEMI 6, 7

Antiplatelet Therapy

• The American Heart Association recommends administering aspirin 162-325 mg initially, followed by 75-162 mg daily indefinitely, and adding a P2Y12 inhibitor to aspirin for dual antiplatelet therapy in patients with NSTEMI 8, 9

Management Strategy Selection

• The American College of Cardiology indicates that an early invasive strategy is appropriate for patients with NSTEMI who have recurrent symptoms 7

Long-term Management and Secondary Prevention

• The American Heart Association recommends continuing aspirin 75-162 mg daily indefinitely and initiating ACE inhibitors for patients with heart failure, LV dysfunction, hypertension, or diabetes 8, 9, 10
• The American College of Cardiology suggests considering ARBs for ACE inhibitor-intolerant patients and initiating high-intensity statin therapy regardless of baseline LDL levels 10

Common Pitfalls and Contraindications

• The American College of Cardiology advises avoiding NSAIDs (except for aspirin) during hospitalization due to increased risks of mortality, reinfarction, hypertension, heart failure, and myocardial rupture in patients with NSTEMI 6, 7
• The American College of Cardiology recommends not administering immediate-release dihydropyridine calcium channel blockers without adequate beta-blockade and avoiding intravenous ACE inhibitors within the first 24 hours due to increased risk of hypotension in patients with NSTEMI 6, 7

Management of Non-ST-Elevation Myocardial Infarction (NSTEMI)

Antiplatelet Therapy

• The American Heart Association recommends continuing aspirin indefinitely (Level of evidence: A) 11, 12
• The American Heart Association suggests administering a loading dose of clopidogrel (300-600 mg) if an early conservative strategy is chosen or if percutaneous coronary intervention (PCI) is planned and not started before diagnostic angiography (Level of evidence: A) 11, 13

Anticoagulant Therapy

• The American Heart Association recommends administering parenteral anticoagulation to all NSTEMI patients in addition to antiplatelet therapy 11
• The American Heart Association suggests using unfractionated heparin (UFH) for at least 48 hours or until discharge if administered before diagnostic angiography (Level of evidence: A) 11
• The American Heart Association suggests using enoxaparin for the duration of hospitalization, up to 8 days, if administered before diagnostic angiography (Level of evidence: A) 11
• The American Heart Association suggests using fondaparinux for the duration of hospitalization, up to 8 days, if administered before diagnostic angiography (Level of evidence: B) 11

Post-Angiography Management

• If PCI is selected, the American Heart Association recommends continuing aspirin (Level of evidence: A) and administering a loading dose of P2Y12 inhibitor if not started before diagnostic angiography (Level of evidence: A) 11, 13
• If coronary artery bypass grafting (CABG) is selected, the American Heart Association recommends continuing aspirin (Level of evidence: A) and stopping clopidogrel 5 to 7 days before elective CABG (Level of evidence: B) 11, 13

NSTEMI Treatment Guidelines

Immediate Initial Management

• The American Heart Association recommends administering aspirin 162-325 mg immediately, followed by maintenance dosing of 75-100 mg daily indefinitely, for patients with NSTEMI 14, 15

Antiplatelet Therapy Strategy

• The American College of Cardiology recommends dual antiplatelet therapy with a P2Y12 inhibitor, preferably ticagrelor or prasugrel over clopidogrel, for patients with NSTEMI 14, 15, 16
• The European Society of Cardiology recommends administering a loading dose of ticagrelor 180 mg, then 90 mg twice daily, for patients with NSTEMI 15
• The American Heart Association recommends continuing P2Y12 inhibitor for at least 12 months after NSTEMI, regardless of whether a stent was placed 14, 15

Anticoagulation Strategy

• The European Heart Journal recommends administering parenteral anticoagulation, such as unfractionated heparin, to all NSTEMI patients in addition to antiplatelet therapy 15

Risk Stratification and Management Strategy Selection

• The American College of Cardiology recommends an early invasive strategy, with angiography within 24-48 hours, for high-risk patients with NSTEMI, including those with elevated cardiac biomarkers or high GRACE or TIMI risk scores 14
• The American Heart Association recommends a conservative strategy for lower-risk patients without ongoing ischemia 14

Post-Angiography Management

• The American College of Cardiology recommends continuing aspirin indefinitely and administering a P2Y12 inhibitor loading dose if not given before angiography, for patients who undergo PCI 14, 15

Long-Term Secondary Prevention

• The American Heart Association recommends measuring left ventricular ejection fraction (LVEF) in all patients with NSTEMI, and considering diagnostic angiography if LVEF is ≤0.40 14
• The American College of Cardiology recommends initiating ACE inhibitors for patients with heart failure, LV dysfunction, hypertension, or diabetes, and considering ARBs for patients intolerant to ACE inhibitors 14, 17
• The European Society of Cardiology recommends high-intensity statin therapy for all patients with NSTEMI, regardless of baseline LDL levels 14, 15
• The American Heart Association recommends adding warfarin to DAPT for patients requiring long-term oral anticoagulation, with a target INR of 2.0-3.0 14, 17

Management of Non-ST-Elevation Myocardial Infarction (NSTEMI)

Antiplatelet Therapy

• The European Society of Cardiology recommends ticagrelor as the preferred P2Y12 inhibitor for all NSTEMI patients, with a loading dose of 180 mg, then 90 mg twice daily, due to superior outcomes 18
• The American College of Cardiology recommends continuing P2Y12 inhibitor for at least 12 months after NSTEMI, regardless of whether a stent was placed, to reduce the risk of subsequent cardiovascular events 18

Anticoagulation Strategy

• The European Heart Journal recommends that all NSTEMI patients require parenteral anticoagulation in addition to antiplatelet therapy, with options including enoxaparin, fondaparinux, or unfractionated heparin 18
• If fondaparinux is used, the European Heart Journal recommends adding unfractionated heparin during PCI to prevent catheter thrombosis 18

Risk Stratification and Invasive Strategy Timing

• The European Heart Journal recommends an immediate invasive strategy (<2 hours) for very high-risk patients with refractory or recurrent angina, hemodynamic instability, or life-threatening arrhythmias, among other criteria 18
• The European Heart Journal recommends an early invasive strategy (<24 hours) for high-risk patients with elevated cardiac biomarkers, dynamic ST-segment or T-wave changes, or high GRACE score, among other criteria 18

Glycoprotein IIb/IIIa Inhibitors

• The American Heart Association recommends against the routine upstream use of GP IIb/IIIa inhibitors, citing increased bleeding risk without reduction in ischemic events 19

Post-Angiography Management

• The European Heart Journal recommends discontinuing ticagrelor 5 days before elective CABG, and prasugrel at least 7 days before CABG, to reduce bleeding risk 18

Long-Term Secondary Prevention

• The American College of Cardiology recommends high-intensity statin therapy, beta-blockers, and ACE inhibitors as mandatory interventions for long-term secondary prevention in NSTEMI patients 18

NSTEMI Anticoagulation in Complex Medical History

Immediate Anticoagulation Strategy

• The American College of Cardiology recommends that all NSTEMI patients require parenteral anticoagulation in addition to antiplatelet therapy, regardless of whether an invasive or conservative strategy is planned 20
• For patients with NSTEMI and complex medical history, including liver disease, kidney disease, and respiratory issues, parenteral anticoagulation should be initiated immediately with agent selection based on renal function 21, 20

Agent Selection Based on Renal Function

• For patients with normal to mild renal impairment, enoxaparin or fondaparinux are reasonable alternatives to UFH, with continuation for the duration of hospitalization up to 8 days 21, 20
• For patients with moderate renal impairment, enoxaparin dose adjustment is required, and bivalirudin or UFH may be considered as they do not require renal dose adjustment 21, 20
• For patients with severe renal impairment or end-stage renal disease, UFH is preferred as it does not accumulate with renal dysfunction 21, 20

Special Considerations for Liver Disease

• For patients with hepatic impairment, UFH is preferred as it can be monitored with aPTT and does not undergo hepatic metabolism 20
• Avoid enoxaparin and fondaparinux in severe liver disease due to unpredictable pharmacokinetics 22

Bleeding Risk Stratification

• For patients with increased bleeding risk, fondaparinux or bivalirudin are reasonable first choices, with a Class IIa, LOE B recommendation for fondaparinux and a Class IIa, LOE A recommendation for bivalirudin 21, 20
• The CRUSADE bleeding risk score should be calculated to quantify bleeding risk 23, 24

Duration of Anticoagulation

• Continue UFH for at least 48 hours or until discharge if given before diagnostic angiography 21, 20
• Continue enoxaparin or fondaparinux for the duration of hospitalization, up to 8 days, if given before diagnostic angiography 21, 20

Critical Pitfalls to Avoid

• Do not switch between anticoagulants as this increases bleeding risk 21, 20
• Do not use fondaparinux as the sole anticoagulant during PCI—it must be supplemented with UFH due to risk of catheter thrombosis 21, 22, 20

Long-Term Anticoagulation Considerations

• For patients requiring long-term oral anticoagulation, use triple antithrombotic therapy for the shortest duration possible, typically 1 week to 1 month 24
• Minimize the duration of triple therapy to limit bleeding risk, which increases from 4-6% with dual therapy to 10-14% with triple therapy 24

Management of NSTEMI

Diagnostic Approach

• Obtain 12-lead ECG within 10 minutes of arrival to distinguish STEMI from NSTE-ACS, as recommended by the American Heart Association and the European Society of Cardiology 25, 26
• Administer supplemental oxygen only if arterial oxygen saturation is <90%, according to the European Heart Journal guidelines 26

Anti-Ischemic Therapy

• Give sublingual or intravenous nitroglycerin for ongoing chest pain, unless systolic blood pressure <90 mmHg, severe bradycardia or tachycardia, right ventricular infarction, or recent phosphodiesterase inhibitor use within 24-48 hours, as suggested by the European Heart Journal 26

Risk Stratification and Timing of Invasive Strategy

• Indicated for very high-risk patients with acute heart failure, according to the European Heart Journal guidelines 26
• Indicated for high-risk patients with elevated cardiac troponin with high-risk features, as recommended by the American Heart Association and the European Society of Cardiology 25, 26
• Diabetes mellitus is a high-risk feature that indicates an early invasive strategy, according to the European Heart Journal guidelines 26

Antithrombotic Strategy

• Agent selection based on strategy and renal function: unfractionated heparin or enoxaparin for early invasive strategy, as recommended by the European Heart Journal guidelines 26
• Fondaparinux is preferred for conservative strategy due to lower bleeding risk, according to the European Heart Journal guidelines 26
• Unfractionated heparin is preferred for severe renal impairment (CrCl <30 mL/min), as suggested by the European Heart Journal guidelines 26

Management of Non-ST-Elevation Myocardial Infarction (NSTEMI)

Anticoagulant Therapy

• The American College of Cardiology recommends administering parenteral anticoagulation to all NSTEMI patients in addition to antiplatelet therapy, with options including unfractionated heparin (UFH), enoxaparin, fondaparinux, and bivalirudin 27, 28
• For patients with severe renal impairment (CrCl <30 mL/min), the American College of Cardiology prefers UFH as it does not accumulate with renal dysfunction 27, 28
• The American College of Cardiology recommends continuing UFH for at least 48 hours or until discharge if given before angiography, and continuing enoxaparin for the duration of hospitalization, up to 8 days, if given before angiography 27, 28

Risk Stratification and Invasive Strategy Timing

• The American College of Cardiology recommends an immediate invasive strategy (<2 hours) for very high-risk patients, including those with refractory or recurrent angina, hemodynamic instability, cardiogenic shock, life-threatening arrhythmias, or cardiac arrest 27
• The American College of Cardiology recommends an early invasive strategy (<24-48 hours) for high-risk patients, including those with elevated cardiac biomarkers, dynamic ST-segment or T-wave changes, high GRACE or TIMI risk score, or diabetes mellitus 27, 29

Post-Angiography Management

• The American College of Cardiology recommends continuing aspirin and administering a P2Y12 inhibitor loading dose if not started before diagnostic angiography, for patients undergoing PCI 27, 28, 29
• The American College of Cardiology recommends discontinuing anticoagulant therapy after PCI for uncomplicated cases 27, 29, 30

Long-Term Secondary Prevention

• The American College of Cardiology recommends measuring LVEF in all patients, and initiating ACE inhibitors for patients with heart failure, LV dysfunction, hypertension, or diabetes 31, 30

Heparin Use in NSTEMI Patients with Active Gastrointestinal Bleeding

Indications for Heparin Despite Active Bleeding

• In NSTEMI patients with active gastrointestinal bleeding, heparin may be justified when ongoing refractory ischemia persists despite optimal anti‑ischemic therapy, indicating a high thrombotic risk that outweighs bleeding concerns. 32

Situations Favoring Heparin Avoidance

• Heparin should be withheld when the same patients have ischemic symptoms adequately controlled by anti‑ischemic medications, reflecting a lower thrombotic urgency. 32

Conservative Management When Bleeding Risk Dominates

• If the bleeding risk exceeds the thrombotic risk, a conservative strategy without any anticoagulant (including heparin) is recommended. 32

Antiplatelet Therapy Recommendations

• Aspirin monotherapy (provided it is tolerated) combined with beta‑blockers, nitrates, and statins is advised for NSTEMI patients with active gastrointestinal bleeding when anticoagulation is omitted. 32
• Aspirin reduces mortality in NSTEMI and should be continued unless the gastrointestinal bleeding is life‑threatening. 32
• Dual antiplatelet therapy (e.g., clopidogrel, ticagrelor, prasugrel) must be deferred until the bleeding source is controlled. 33

Agents to Exclude in Active Bleeding

• Glycoprotein IIb/IIIa inhibitors should not be administered in the setting of active gastrointestinal bleeding. 32

Management of NSTEMI in Patients with Active Rectal Bleeding

Antithrombotic Therapy

• In NSTEMI patients who exhibit very high‑risk features (hemodynamic instability, cardiogenic shock, life‑threatening arrhythmias, or cardiac arrest), the immediate mortality risk may outweigh bleeding risk, justifying the use of heparin despite active rectal bleeding. 34
• When anticoagulation is deemed absolutely necessary, fondaparinux has the lowest bleeding risk among available agents, although it still carries a significant risk in the setting of active gastrointestinal bleeding. [34][35]

Anti‑Ischemic and Adjunctive Pharmacotherapy

• Maximizing beta‑blocker therapy is recommended to reduce myocardial oxygen demand in NSTEMI patients with active rectal bleeding. [34][35]
• Nitrate administration (sublingual or intravenous) should be used for ongoing chest pain unless contraindicated, even in the presence of active gastrointestinal bleeding. 34
• High‑intensity statin therapy should be initiated promptly in all NSTEMI patients, regardless of bleeding status, to improve cardiovascular outcomes. 36

Invasive Strategy Timing

• An immediate invasive coronary strategy (angiography within ≤ 2 hours) is indicated only if refractory ischemia, hemodynamic instability, or life‑threatening arrhythmias persist despite optimal medical therapy. 34
• An early invasive strategy (angiography within 24–48 hours) may be pursued once gastrointestinal bleeding is controlled and the patient is hemodynamically stable. 34

Gastro‑Intestinal Protection

• Proton‑pump inhibitor therapy is recommended for NSTEMI patients on aspirin monotherapy who are at high risk for gastrointestinal bleeding, such as those with a history of rectal bleeding. 36

Monitoring

• Serial cardiac troponin measurements are advised to assess infarct evolution in NSTEMI patients with active bleeding. 34

Heparin Anticoagulation in NSTEMI

Immediate Anticoagulation Strategy

• All patients presenting with NSTEMI should receive parenteral anticoagulation (unfractionated heparin [UFH] or low‑molecular‑weight heparin [LMWH]) in addition to antiplatelet therapy at the time of presentation. ACC/AHA guideline 37, 38

UFH Dosing and Monitoring

• UFH is administered with an initial bolus of 60 U/kg (maximum 4,000 U) followed by a continuous infusion of 12 U/kg/h (maximum 1,000 U/h); the target activated partial thromboplastin time (aPTT) is 1.5–2.0 × control (≈50–70 s). ACC/AHA guideline 37

LMWH (Enoxaparin) Dosing

• Enoxaparin is given 1 mg/kg subcutaneously every 12 h (maximum 10,000 IU twice daily); routine laboratory monitoring is not required because of its predictable pharmacokinetics. ESC guideline 39

Duration of Anticoagulation

• UFH should be continued for at least 48 h or until percutaneous coronary intervention (PCI) is performed, whichever occurs first; extending UFH beyond 48 h without a specific indication is not recommended. ACC/AHA and ACC guidelines 37, 40
• Enoxaparin or fondaparinux may be continued for the duration of the hospital stay, up to 8 days. ACC/AHA and ACC guidelines 37, 40

Early Invasive (PCI) Strategy

• When PCI is planned within 24 h, UFH is continued through the procedure with additional boluses to maintain a therapeutic activated clotting time (ACT): 250–300 s (HemoTec) or 300–350 s (Hemochron) when GP IIb/IIIa inhibitors are not used. ACC/AHA guideline 41
• If GP IIb/IIIa inhibitors are administered, the target ACT is ≈200 s. ACC/AHA guideline 41
• Anticoagulation is discontinued immediately after an uncomplicated PCI. ACC/AHA and ACC guidelines 37, 40

Enoxaparin Management During PCI

• No additional enoxaparin dose is required if the last dose was given ≤ 8 h before PCI. ACC/AHA guideline 41
• If the last dose was 8–12 h prior, give an IV bolus of 0.3 mg/kg before PCI. ACC/AHA guideline 41
• Enoxaparin is otherwise continued through PCI. ACC/AHA guideline 37

Conservative (Non‑Invasive) Strategy

• With a conservative approach, UFH is administered for ≥ 48 h, while enoxaparin or fondaparinux are continued for the hospital stay (up to 8 days). ACC/AHA and ACC guidelines 37, 40

Pre‑CABG Anticoagulation Management

• UFH is continued through coronary artery bypass grafting (CABG). ACC/AHA and ACC guidelines 37, 40
• Enoxaparin should be stopped 12–24 h before CABG and the patient switched to UFH. ACC/AHA and ACC guidelines 37, 40
• Fondaparinux should be stopped 24 h before CABG and the patient switched to UFH. ACC/AHA and ACC guidelines 37, 40
• Bivalirudin should be stopped 3 h before CABG and the patient switched to UFH. ACC/AHA and ACC guidelines 37, 40

Antiplatelet Therapy

• Aspirin loading 162–325 mg followed by 75–162 mg daily indefinitely. ACC/AHA guideline 37, 38
• Clopidogrel loading 300–600 mg followed by 75 mg daily for at least 12 months. ACC/AHA and ACC guidelines 37, 40

Clinical Outcomes

• Adding heparin to aspirin provides an incremental but modest benefit over aspirin alone. ACC/AHA and ESC guidelines 38, 39
• Triple therapy (aspirin + P2Y12 inhibitor + GP IIb/IIIa inhibitor) yields additional benefit in high‑risk patients but is associated with a higher bleeding risk. ACC/AHA guideline 38

NSTEMI Immediate Diagnosis and Risk‑Stratified Invasive Management

1. Early Electrocardiographic Assessment

• Obtain a 12‑lead ECG within 10 minutes of first medical contact and interpret it immediately to differentiate NSTEMI from STEMI, as recommended by the European Society of Cardiology (ESC) guidelines. 42

2. Antiplatelet Agent Selection After Angiography

• Use prasugrel (loading 60 mg, then 10 mg daily; dose reduction to 5 mg daily in elderly or low‑weight patients) only after coronary angiography and before PCI in patients who have not previously received a P2Y12 inhibitor, according to ESC guidance. 42

3. Timing of Invasive Coronary Angiography Based on Clinical Risk

3.1 Immediate Invasive Strategy (< 2 h)

• Indicated for patients with refractory or recurrent angina despite optimal medical therapy.
• Indicated for patients with hemodynamic instability or cardiogenic shock.
• Indicated for patients experiencing life‑threatening arrhythmias or cardiac arrest.
• These criteria are endorsed by the ESC for urgent angiography. 42

3.2 Early Invasive Strategy (< 24 h)

• Recommended when high‑sensitivity cardiac troponin is elevated together with high‑risk clinical features.
• Also appropriate for patients with dynamic ST‑segment or T‑wave changes, high GRACE or TIMI risk scores, or diabetes mellitus. (ESC recommendation) 42

3.3 Standard Invasive Strategy (< 72 h)

• Applied to intermediate‑risk patients who are symptom‑stable but meet at least one intermediate‑risk criterion (e.g., modest biomarker rise, moderate GRACE score). ESC guidance supports this timing. 42

3.4 Conservative (Non‑Invasive) Strategy

• Suitable for patients with a low GRACE score and no ongoing ischemia.
• Also appropriate for patients with significant comorbidities where the procedural risk outweighs potential benefit. These recommendations follow ESC risk‑stratification algorithms. 42

Guideline‑Based Management of NSTEMI with Active Gastrointestinal Bleeding

Aspirin Management

• Continue low‑dose aspirin 81 mg daily in NSTEMI patients with active gastrointestinal bleeding, unless the bleeding is immediately life‑threatening; the cardiovascular mortality benefit outweighs bleeding risk (American College of Cardiology/American Heart Association, Class I, Level A) 43.
• Maintain aspirin therapy indefinitely for as long as any antithrombotic agent is administered, because a prior upper‑GI bleed is the strongest predictor of recurrent bleeding (American College of Cardiology/American Heart Association, Class I, Level B) 43.

Proton‑Pump Inhibitor (PPI) Strategy

• Initiate high‑dose intravenous PPI immediately (80 mg bolus followed by continuous infusion of 8 mg/h for 72 h) and then switch to standard once‑daily oral PPI (e.g., pantoprazole 40 mg) while antithrombotic therapy is continued (American College of Cardiology/American Heart Association, Class I, Level B) 43.
• Continue oral PPI indefinitely for as long as antithrombotic therapy is required, given the high risk of recurrent upper‑GI bleeding (European Society of Cardiology, Class I, Level B) 44.

Dual Antiplatelet Therapy After PCI

• If percutaneous coronary intervention with stent placement is performed, prescribe dual antiplatelet therapy (aspirin + clopidogrel) for at least 12 months unless bleeding risk clearly outweighs the benefit (European Society of Cardiology, Class I, Level A) 44.

Anticoagulation Combined with Dual Antiplatelet Therapy

• When oral anticoagulation is required together with dual antiplatelet therapy, target an INR of 2.0–2.5 (lower than the standard 2.5–3.5 range) to mitigate bleeding risk (American College of Cardiology/American Heart Association, Class IIa, Level B) 43.
• This lower INR target is supported by evidence from a 2012 study demonstrating reduced bleeding without compromising thrombotic protection (American College of Cardiology/American Heart Association, Class IIb, Level B) 45.

NSTEMI Management: Dual Antiplatelet Therapy and Anticoagulation Guidelines

Antiplatelet Loading

• Aspirin loading – Give a 162–325 mg chewable, non‑enteric‑coated dose immediately on presentation, followed by a maintenance dose of 75–100 mg daily indefinitely. (European Society of Cardiology, 2021) 46

P2Y12 Inhibitor Selection

• Ticagrelor – A 180 mg loading dose (then 90 mg twice daily) is the preferred P2Y12 inhibitor for all NSTEMI patients, irrespective of whether an invasive or a conservative strategy is planned. (ESC, 2021) 46
• Prasugrel – A 60 mg loading dose (then 10 mg daily; reduce to 5 mg if age ≥ 75 years or weight < 60 kg) should be considered for patients who will undergo PCI, but only after coronary anatomy has been defined. (American College of Cardiology/American Heart Association, 2013; ESC, 2021) [47][46]
• Clopidogrel – A 600 mg loading dose (then 75 mg daily) is reserved for situations where prasugrel or ticagrelor are unavailable, contraindicated, or not tolerated. (ESC, 2021) 46
• Contraindication for prasugrel – Prasugrel must not be used in patients with a prior stroke or transient ischemic attack because it increases harm in this population. (ACC/AHA, 2013) 47

Immediate Parenteral Anticoagulation

• Universal requirement – All NSTEMI patients need immediate parenteral anticoagulation in addition to dual antiplatelet therapy, regardless of the planned invasive or conservative approach. (ESC, 2021) 46
• Enoxaparin dosing (CrCl > 30 mL/min) – 1 mg/kg administered subcutaneously every 12 hours. (ESC, 2021) 46
• UFH duration – Continue unfractionated heparin for at least 48 hours or until PCI is performed, whichever occurs first. (ACC/AHA, 2012) 48
• Enoxaparin or fondaparinux duration – Continue for the length of the hospital stay, up to a maximum of 8 days. (ACC/AHA, 2012; ACC/AHA, 2013) [48][47]

Timing of Invasive Strategy

• Immediate invasive (< 2 h) – Indicated for refractory or recurrent angina despite optimal medical therapy, hemodynamic instability or cardiogenic shock, and life‑threatening arrhythmias or cardiac arrest. (ESC, 2021) 46
• Early invasive (< 24 h) – Indicated for elevated cardiac troponin with high‑risk features, dynamic ST‑segment or T‑wave changes, high GRACE or TIMI risk scores, and diabetes mellitus. (ESC, 2021) 46
• Conservative strategy – Appropriate for patients with a low GRACE score without ongoing ischemia and for those whose comorbidities make procedural risk exceed expected benefit. (ESC, 2021) 46

Pre‑treatment with P2Y12 Inhibitors

• Routine pre‑treatment discouraged – The 2021 ESC guidelines advise against routine pre‑loading with P2Y12 inhibitors when coronary anatomy is unknown and an early invasive strategy is planned, to avoid unnecessary bleeding and to preserve the option of prasugrel. (ESC, 2021) 46
• Early ticagrelor loading permissible – Ticagrelor may still be administered early because it can be used irrespective of coronary anatomy. (ESC, 2021) 46

Glycoprotein IIb/IIIa Inhibitor Use

• Bail‑out only – Glycoprotein IIb/IIIa inhibitors should not be used routinely or upstream; they are reserved for bail‑out situations such as no‑reflow or thrombotic complications during PCI. (ESC, 2021) 46

Duration of Dual Antiplatelet Therapy (DAPT)

• Standard duration – Continue DAPT for at least 12 months after NSTEMI, regardless of whether a stent was placed. This recommendation is Class I, Level B evidence and applies to clopidogrel, prasugrel, and ticagrelor. (ACC/AHA, 2012; ACC/AHA, 2013; ESC, 2021) [48][47]46
• Bleeding‑risk exception – If the bleeding risk clearly outweighs the ischemic benefit, earlier discontinuation of DAPT may be considered. (ACC/AHA, 2012; ACC/AHA, 2013) [48][47]

Pre‑CABG Antiplatelet Management

• Clopidogrel cessation – Stop clopidogrel 5–7 days before an elective coronary artery bypass graft operation. (ACC/AHA, 2013) 47

All statements are derived from guideline societies (ESC, ACC/AHA) and reflect the cited evidence levels where provided.

Guideline Recommendations for Management of Non‑ST‑Elevation Myocardial Infarction (NSTEMI)

Immediate Initial Management

• Obtain a 12‑lead electrocardiogram within 10 minutes of first medical contact to confirm NSTEMI (absence of persistent ST‑elevation with elevated troponin). European Society of Cardiology (ESC) 2021 49
• Admit the patient to a monitored unit with continuous rhythm monitoring for at least 24 hours (longer if arrhythmia risk is high). ESC 2021 49
• Provide supplemental oxygen only when arterial oxygen saturation is < 90 %. ESC 2021 49
• Give sublingual or intravenous nitroglycerin for ongoing ischemic chest pain unless contraindicated by systolic BP < 90 mmHg, severe brady‑/tachycardia, right‑ventricular infarction, or recent phosphodiesterase‑inhibitor use. ESC 2021 49

Antiplatelet Therapy Strategy

• Ticagrelor (180 mg loading, then 90 mg twice daily) is the preferred P2Y12 inhibitor for all NSTEMI patients, irrespective of planned invasive or conservative management. ESC 2021 49
• Prasugrel (60 mg loading, then 10 mg daily; reduce to 5 mg if age ≥ 75 yr or weight < 60 kg) should be considered for patients proceeding to PCI only after coronary anatomy is defined to avoid use in those with prior stroke/TIA. American College of Cardiology (ACC) 2011 50
• Reserve clopidogrel (300‑600 mg loading, then 75 mg daily) for situations where ticagrelor or prasugrel are unavailable, contraindicated, or not tolerated. ESC 2021 49
• Continue the chosen P2Y12 inhibitor for at least 12 months after NSTEMI, regardless of stent placement. ESC 2021 49
• Do not routinely pre‑treat with a P2Y12 inhibitor when coronary anatomy is unknown and an early invasive strategy is planned, to preserve the option of prasugrel and limit bleeding. ESC 2021 49

Anticoagulation Strategy

• Immediate parenteral anticoagulation is required for all NSTEMI patients in addition to dual antiplatelet therapy. ESC 2021 49

Agent Selection (based on renal function)

Dosing & Duration

• UFH: Initial bolus 60 U/kg (max 4,000 U) followed by continuous infusion 12 U/kg/h (max 1,000 U/h); target aPTT 1.5‑2.0 × control (≈50‑70 s). Continue ≥ 48 h or until PCI is performed. ACC 2011 [50][51]
• Enoxaparin: 1 mg/kg SC q12 h; continue through hospitalization up to 8 days. ACC 2011 [50][51]
• Fondaparinux: Continue through hospitalization up to 8 days. ACC 2011 [50][51]

Timing of Invasive Strategy (Risk‑Stratified)

• Immediate invasive (< 2 h) for very high‑risk patients with any of: refractory/recurrent angina, hemodynamic instability or cardiogenic shock, life‑threatening arrhythmias or cardiac arrest, or acute heart failure. ESC 2021 49; ACC 2014 52
• Early invasive (< 24 h) for high‑risk patients with: elevated troponin plus high‑risk features, dynamic ST‑segment/T‑wave changes, high GRACE or TIMI score, or diabetes mellitus. ESC 2021 49; ACC 2014 52
• Standard invasive (< 72 h) for intermediate‑risk, symptom‑stable patients meeting at least one intermediate‑risk criterion (e.g., modest biomarker rise, moderate GRACE score). (Guideline‑based inference; no specific citation needed)

Glycoprotein IIb/IIIa Inhibitor Use

• Do not use glycoprotein IIb/IIIa inhibitors routinely or upstream; reserve for bail‑out situations such as no‑reflow or thrombotic complications during PCI. ESC 2021 49
• Avoid GP IIb/IIIa antagonists when coronary anatomy is unknown. ESC 2021 49

Contraindication to Fibrinolysis

• Fibrinolytic therapy should never be administered in NSTEMI without ST‑segment elevation. ACC 2014 52

Post‑Angiography Management

If Percutaneous Coronary Intervention (PCI) Is Performed

• Continue aspirin indefinitely. ACC/JACC 2007 53
• Give a loading dose of the selected P2Y12 inhibitor if not already administered before diagnostic angiography. ACC/JACC 2007 53
• Discontinue the parenteral anticoagulant after PCI for uncomplicated cases. ACC/JACC 2007 53

If Coronary Artery Bypass Grafting (CABG) Is Planned

• Continue aspirin indefinitely. ACC/JACC 2007 53
• Stop clopidogrel 5‑7 days before elective CABG. ACC/JACC 2007 53
• Maintain UFH throughout the peri‑operative period. ACC/JACC 2007 53
• Switch from enoxaparin to UFH 12‑24 h before CABG. ACC/JACC 2007 53
• Switch from fondaparinux to UFH 24 h before CABG. ACC/JACC 2007 53
• Switch from bivalirudin to UFH 3 h before CABG. ACC/JACC 2007 53
• Discontinue IV GP IIb/IIIa inhibitor (eptifibatide or tirofiban) 4 h before CABG. ACC/JACC 2007 53

If a Conservative (Medical‑Only) Strategy Is Chosen

• Continue aspirin indefinitely. ACC/JACC 2007 53
• Provide a loading dose of clopidogrel if not given before angiography. ACC/JACC 2007 53
• Continue UFH for at least 48 h, or discontinue enoxaparin/fondaparinux for the duration of hospitalization. ACC/JACC 2007 53

Stress Testing After Conservative Management

• Perform non‑invasive stress testing 24‑48 h after achieving clinical stability to evaluate for inducible ischemia. ACC 2011 [51][50]